# To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Study · id `cardio:ct-nct05702073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05702073](<https://clinicaltrials.gov/study/NCT05702073>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05702073

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.

## Technical summary

Registry record NCT05702073. Randomized; no masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-06-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 423 participants (enrolled count; ClinicalTrials.gov record NCT05702073, source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)
- Started: 2023-03-31 (actual) (ClinicalTrials.gov record NCT05702073, source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)
- Primary completion: 2024-06-11 (actual) (ClinicalTrials.gov record NCT05702073, source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)
- Completion: 2024-06-11 (actual) (ClinicalTrials.gov record NCT05702073, source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05702073, source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05702073-2025-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): INS068 injection
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 9530e9b74de34e623352231557eebc97213c9749d3e45ba789cfd9a12618a90e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
